Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Operations data on file, last reported at 14730000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 66.35% year-over-year to 14730000.0 in Q1 2026; TTM through Mar 2026 was 38803000.0, a 76.82% increase from a year earlier, with the FY2025 full-year figure at 67851000.0, up 62.05% from the prior year.
• Cash from Operations for Q1 2026 stood at 14730000.0, up from 17233000.0 in the prior quarter.
• Over the last five years, Cash from Operations for LXRX reached as high as 16993000.0 in Q2 2025 and fell as low as 55130000.0 in Q1 2024.
• Historically, Cash from Operations has averaged 30124058.82 across 5 years, with a median of 24422000.0 in 2022.
• Across the five-year window, Cash from Operations plunged 134.35% in 2023 and jumped 135.01% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 21569000.0 in 2022, then sank by 134.35% to 50548000.0 in 2023, then surged by 57.48% to 21491000.0 in 2024, then rose by 19.81% to 17233000.0 in 2025, then advanced by 14.52% to 14730000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 14730000.0 in Q1 2026, 17233000.0 in Q4 2025, and 23833000.0 in Q3 2025.